We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

41 hedge funds and large institutions have $254M invested in UroGen Pharma in 2017 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 4

76% more capital invested

Capital invested by funds: $145M → $254M (+$110M)

63% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 8

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

32% more funds holding

Funds holding: 31 → 41 (+10)

16.73% more ownership

Funds ownership: 35.14% → 51.88% (+17%)

Holders
41
Holders Change
+10
Holders Change %
+32.26%
% of All Funds
0.93%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
14
Increased
13
Reduced
8
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MMH
Menora Mivtachim Holdings
Israel
+$33.5M
2
CCM
Consonance Capital Management
New York
+$32.6M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$8.18M
4
CS
Credit Suisse
Switzerland
+$4.42M
5
Renaissance Technologies
Renaissance Technologies
New York
+$3.76M

Top Sellers

Rank Fund Capital Flow
1
PAI
ProQuest Associates IV
Florida
-$12.6M
2
Jennison Associates
Jennison Associates
New York
-$4.68M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.83M
4
PA
Perceptive Advisors
New York
-$2.49M
5
BII
Bainco International Investors
Massachusetts
-$2.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
MMH
1
Menora Mivtachim Holdings
Israel
$56.2M +$33.5M +940,418 +165%
PAI
2
ProQuest Associates IV
Florida
$40.8M -$12.6M -353,721 -24%
CCM
3
Consonance Capital Management
New York
$34.1M +$32.6M +916,450 New
Fidelity Investments
4
Fidelity Investments
Massachusetts
$25.7M -$2.83M -79,400 -10%
Wellington Management Group
5
Wellington Management Group
Massachusetts
$19.3M +$8.18M +229,828 +79%
MIH
6
Meitav Investment House
Israel
$15.4M +$14.7M +412,882 New
HCM
7
Highline Capital Management
New York
$14.9M -$360K -10,100 -2%
CS
8
Credit Suisse
Switzerland
$8.34M +$4.42M +124,000 +124%
PA
9
Perceptive Advisors
New York
$7.41M -$2.49M -70,000 -26%
DP
10
DSAM Partners
United Kingdom
$5.08M +$2.21M +62,000 +83%
Renaissance Technologies
11
Renaissance Technologies
New York
$4.88M +$3.76M +105,500 +412%
WCM
12
Wildcat Capital Management
New York
$4.74M -$274K -7,687 -6%
SIM
13
Spark Investment Management
New York
$2.63M +$1.2M +33,600 +91%
LSC
14
Lyon Street Capital
California
$2.11M +$530K +14,876 +36%
Deutsche Bank
15
Deutsche Bank
Germany
$1.89M +$1.22M +34,291 +209%
LCM
16
Laurion Capital Management
New York
$1.77M +$1.69M +47,473 New
CBA
17
Coastal Bridge Advisors
Connecticut
$1.49M – – –
Morgan Stanley
18
Morgan Stanley
New York
$1.24M +$347K +9,756 +41%
Acadian Asset Management
19
Acadian Asset Management
Massachusetts
$884K -$30.4K -853 -3%
SAM
20
Shikiar Asset Management
New York
$782K -$2.67K -75 -0.4%
USAA
21
United Services Automobile Association
Texas
$700K +$670K +18,816 New
AA
22
ALPS Advisors
Colorado
$543K +$100K +2,813 +24%
JMPWA
23
JP Morgan Private Wealth Advisors
California
$456K – – –
Millennium Management
24
Millennium Management
New York
$427K +$409K +11,485 New
GCP
25
GSA Capital Partners
United Kingdom
$380K +$32K +900 +10%
1
2

URGN Hedge Fund Activity: Q4 2017 in Review

41 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q4 2017, worth a combined $254M — up 76% from $145M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new URGN positions and 4 closed out — a net gain of 10 holders — while 13 added to existing stakes and 8 trimmed.

The largest buyer was Menora Mivtachim Holdings, adding an estimated $33.5M. The largest seller was ProQuest Associates IV, cutting an estimated $12.6M.

  • 41 institutional investors held UroGen Pharma (URGN) as of Q4 2017, up from 31 in Q3 2017.
  • Funds reported $254M of UroGen Pharma stock for Q4 2017, up 76% quarter-over-quarter.
  • 14 funds opened new UroGen Pharma positions in Q4 2017 and 4 closed out, a net change of +10 holders.
  • The largest UroGen Pharma buyer in Q4 2017 was Menora Mivtachim Holdings, an estimated $33.5M added.
  • The largest UroGen Pharma seller in Q4 2017 was ProQuest Associates IV, an estimated $12.6M sold.

Based on aggregated 13F filings for Q4 2017.